MET is a popular target and several clinical trials are underway to evaluate monoclonal antibodies, such as rilotumumab (AMG102), onartuzumab (MetMAb), ABT-700 as well as MET-specific and multi-targeted small-molecule tyrosine-kinase inhibitors, for the treatment of GC. This evidence concerns the gene MET and gastric cancer.